No EU Ban On Direct Selling Of OTCs

24 February 1997

The new European Union (Parliament and Council) Directive on theProtection of Consumers in Respect of Contracts Negotiated at a Distance contains no direct prohibition on distance selling of over-the-counter medicines, although national bans will be tolerated, notes the European Proprietary Medicines Manufacturers Association (AESGP).

The Directive states: "whereas a member state may ban, in the general interest, the marketing on its territory of certain goods and services through contracted negotiated at a distance; whereas that ban must comply with Community rules; whereas there is already provision for such bans, notably in regard to medicinal products under Council Directive 89/552/EEC on the coordination of certain provisions laid down by law, regulation or administration active in member states concerning the pursuit of television broadcasting activities and Council Directive 92/28/EEC of March 31, 1992 on the advertising of medicinal products for human use."

Article 14 reads: "Member states may introduce or maintain, in the area covered by this Directive, more stringent provisions compatible with the Treaty, to ensure a higher level of consumer protection. Such provisions shall, where appropriate, include the prohibition, in the general interest, of the marketing of certain goods or services, particularly medicinal products, in their territory by means of distance contracts, with due regard for the Treaty."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight